MBBS, MCPS (medicine), FCPS Cardiology, Fellowship in Coronary and Peripheral Intervention, Seoul, South Korea; Assistant Professor Cardiology, Department of Cardiology, MTI Lady Reading Hospital Peshawar, Pakistan.
Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
Indian Heart J. 2022 May-Jun;74(3):182-186. doi: 10.1016/j.ihj.2022.05.002. Epub 2022 May 13.
It has been reported that significant endothelial dysfunction or clinically evident vasospasm can be associated with drug-eluting stents (DESs). However, the impact of DES associated coronary artery spasm (CAS) on long-term clinical outcomes has not been fully elucidated as compared with those of patients with vasospastic angina.
A total of 2797 consecutive patients without significant coronary artery lesion (<70%), who underwent the Acetylcholine (Ach) provocation test, were enrolled between Nov 2004 and Oct 2010. DES-associated spasm was defined as significant CAS in proximal or distal to previously implanted DES site at follow-up angiography with Ach test. Patients were divided into two groups (DES-CAS; n = 108, CAS; n = 1878). For adjustment, propensity score matching (PSM) was done (C-statistics = 0.766, DES-CAS; n = 102, CAS; n = 102). SPSS 20 (Inc., Chicago, Illinois) was used to analyze this data.
Baseline characteristics were worse in the DES-CAS group. After PSM, both baseline characteristics and the Ach test results were balanced except higher incidence of diffuse CAS and ECG change in the DES-CAS group. During Ach test, the incidence of diffuse spasm (93.1% vs. 81.3%, p = 0.012) and ST-T change (10.7% vs. 1.9%, p = 0.010) were higher in the DES-CAS group. At 3-year, before and after adjustment, the DES-CAS group showed a higher incidence of coronary revascularization (9.8% vs. 0.0%, p = 0.001), recurrent chest pain requiring follow up coronary angiography (CAG, 24.5% vs. 7.8%, p = 0.001) and major adverse cardiac events (MACEs, 9.8% vs. 0.9%, p < 0.005).
In this study, DES associated CAS was associated with higher incidence of diffuse spasm, ST-T change and adverse 3-year clinical outcomes. Special caution should be exercised in this particular subset of patients.
已有报道称,显著的内皮功能障碍或临床明显的血管痉挛可能与药物洗脱支架(DES)有关。然而,与血管痉挛性心绞痛患者相比,DES 相关的冠状动脉痉挛(CAS)对长期临床结局的影响尚未完全阐明。
本研究共纳入了 2797 例连续患者,这些患者的冠状动脉病变不严重(<70%),并于 2004 年 11 月至 2010 年 10 月期间接受了乙酰胆碱(Ach)激发试验。DES 相关痉挛定义为在随访血管造影中使用 Ach 试验时,先前植入 DES 部位的近端或远端出现显著的 CAS。将患者分为两组(DES-CAS 组,n=108;CAS 组,n=1878)。为了进行调整,进行了倾向评分匹配(PSM)(C 统计量=0.766,DES-CAS 组,n=102;CAS 组,n=102)。采用 SPSS 20(芝加哥,伊利诺伊州,美国)分析数据。
DES-CAS 组的基线特征较差。经过 PSM 后,除了 DES-CAS 组弥漫性 CAS 和心电图改变的发生率较高外,两组的基线特征和 Ach 试验结果均达到平衡。在 Ach 试验中,DES-CAS 组弥漫性痉挛的发生率(93.1%比 81.3%,p=0.012)和 ST-T 改变的发生率(10.7%比 1.9%,p=0.010)均较高。在 3 年时,调整前后,DES-CAS 组的冠状动脉血运重建(9.8%比 0.0%,p=0.001)、需要随访冠状动脉造影(CAG)的复发性胸痛(24.5%比 7.8%,p=0.001)和主要不良心脏事件(MACEs,9.8%比 0.9%,p<0.005)的发生率更高。
在本研究中,DES 相关的 CAS 与弥漫性痉挛、ST-T 改变和 3 年不良临床结局的发生率较高相关。对于这一特定亚组的患者,应特别谨慎。